AOS T HESIS Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial

被引:1
作者
Acharya, Nisha R. [1 ,2 ,3 ]
Rathinam, Sivakumar R. [4 ,5 ]
Thundikandy, Radhika [4 ,5 ]
Kanakath, Anuradha [6 ,7 ]
Murugan, S. Bala [8 ]
Vedhanayaki, R. [4 ,5 ]
Gonzales, John A. [2 ]
Lim, Lyndell L. [7 ]
Suhler, Eric B. [9 ]
Al-Dhibi, Hassan A. [10 ]
Doan, Thuy [1 ,2 ]
Arellanes-Garcia, Lourdes [11 ]
Coyne, Alison [1 ]
Porco, Travis C. [1 ,2 ]
Shantha, Jessica G. [1 ,2 ]
机构
[1] Univ Calif San Francisco, FI Proctor Fdn, 490 Illinois St,2nd floor, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
[4] Aravind Eye Hosp, Uvea Serv, Madurai, India
[5] Postgrad Inst Ophthalmol, Madurai, India
[6] Aravind Eye Hosp, Uvea Serv, Coimbatore, India
[7] Postgrad Inst Ophthalmol, Coimbatore, India
[8] Postgrad Inst Ophthalmol, Pondicherry, India
[9] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR USA
[10] King Khalid Eye Specialist Hosp, Div Vitreoretinal Surg & Uveitis, Riyadh, Saudi Arabia
[11] Asociac Evitar Mexico, Mexico City, Mexico
关键词
RANDOMIZED CLINICAL-TRIAL; SUNSET GLOW FUNDUS; MYCOPHENOLATE-MOFETIL; SYSTEMIC CORTICOSTEROIDS; PROGNOSTIC-FACTORS; VISUAL OUTCOMES; METHOTREXATE; THERAPY; IMMUNOSUPPRESSION; STANDARDIZATION;
D O I
10.1016/j.ajo.2024.06.004
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To compare the effectiveness of methotrexate (MTX) and mycophenolate mofetil (MMF) in achieving corticosteroid-sparing control of uveitis in patients with Vogt-Koyanagi-Harada (VKH) disease. Methods: A subanalysis of patients with VKH from the First-line Antimetabolites as Steroid-sparing Treatment Uveitis Trial, a randomized, observer-masked, comparative effectiveness trial, with comparisons by treatment (MTX vs MMF) and disease stage (acute vs chronic). Individuals with noninfectious uveitis were placed on a standardized corticosteroid taper and block randomized 1:1 to either 25 mg weekly oral MTX or 1.5 g twice daily oral MMF. The primary outcome was treatment success defined by corticosteroid-sparing control of uveitis at 6 months. Additional outcomes included change in best spectacle-corrected visual acuity (BSCVA), retinal central subfield thickness (CST), and resolution of serous retinal detachment (SRD). Results: Ninety-three out of 216 enrolled patients had VKH; 49 patients were randomized to MTX and 44 to MMF, of which 85 patients (46 on MTX, 39 on MMF) contributed to the primary outcome. There was no significant difference in treatment success by antimetabolite (80.4% for MTX compared to 64.1% for MMF; P = .12) or in BSCVA improvement (P = .78). MTX was superior to MMF in reducing CST (P = .003) and resolving SRD (P = .02). There was no significant difference in treatment success by disease stage (P = .25), but patients with acute VKH had greater improvement in BSCVA (P < .001) and reduction of CST (P = .02) than chronic VKH patients. Conclusions: MTX and MMF have comparable outcomes as corticosteroid-sparing immunosuppressive therapies for VKH. Visual acuity improvement was greater in acute vs chronic VKH. NOTE: Publication of this article is sponsored by the American Ophthalmological Society (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
引用
收藏
页码:100 / 111
页数:12
相关论文
共 37 条
  • [1] Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of `sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease
    Abu El-Asrar, Ahmed M.
    Dosari, Mona
    Hemachandran, Suhail
    Gikandi, Priscilla W.
    Al-Muammar, Abdulrahman
    [J]. ACTA OPHTHALMOLOGICA, 2017, 95 (01) : 85 - 90
  • [2] Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids
    Abu El-Asrar, Ahmed M.
    Al Tamimi, Mamdouh
    Hemachandran, Suhail
    Al-Mezaine, Hani S.
    Al-Muammar, Abdulrahman
    Kangave, Dustan
    [J]. ACTA OPHTHALMOLOGICA, 2013, 91 (06) : e486 - e493
  • [3] The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease
    Abu El-Asrar, Ahmed M.
    Hemachandran, Suhail
    Al-Mezaine, Hani S.
    Kangave, Dustan
    Al-Muammar, Abdulrahman M.
    [J]. ACTA OPHTHALMOLOGICA, 2012, 90 (08) : e603 - e608
  • [4] Prognostic factors in Vogt-Koyanagi-Harada disease
    Al-Kharashi A.S.
    Aldibhi H.
    Al-Fraykh H.
    Kangave D.
    Abu El-Asrar A.M.
    [J]. International Ophthalmology, 2007, 27 (2-3) : 201 - 210
  • [5] Comparison of Two Different Combination Immunosuppressive Therapies in the Treatment of Vogt-Koyonagi-Harada Syndrome
    Arcinue, Cheryl A.
    Radwan, Alaa
    Lebanan, May O.
    Foster, C. Stephen
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2013, 21 (01) : 32 - 37
  • [6] Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders
    Baltatzis, S
    Tufail, F
    Yu, EN
    Vredeveld, CM
    Foster, CS
    [J]. OPHTHALMOLOGY, 2003, 110 (05) : 1061 - 1065
  • [7] A review of methotrexate-associated hepatotoxicity
    Bath, Roopjeet K.
    Brar, Navkiran K.
    Forouhar, Faripour A.
    Wu, George Y.
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2014, 15 (10) : 517 - 524
  • [8] Bouchenaki Nadia, 2011, J Ophthalmic Vis Res, V6, P241
  • [9] Vogt-Koyanagi-Harada disease
    Burkholder, Bryn M.
    [J]. CURRENT OPINION IN OPHTHALMOLOGY, 2015, 26 (06) : 506 - 511
  • [10] Long-term Outcomes of Limited Vogt-Koyanagi-Harada Syndrome
    Chew, Sky K.
    Levy, Jaime
    Rogers, Sophie
    Lim, Lyndell L.
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 167 : 52 - 56